Zimbabwe has turned down a major American health deal valued at 367 million US dollars (£272m) over five years due to the United States' request for sensitive biological samples.
This rejection became public following a internal memorandum dated December was leaked, revealing that President Emmerson Mnangagwa deemed the arrangement was "unbalanced".
A government spokesman has since explained that the US was seeking health data for research and profit while refused to share the resulting advantages from future vaccines.
"We are forced to start the difficult and regrettable task of scaling back our health assistance in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy indicated the US had furnished more than $1.9bn for health programmes to Zimbabwe during the past two decades.
A physicians' group in Zimbabwe has appealed for more negotiations to secure a agreement suitable to all parties so the nation's vital HIV programme can be sustained.
Wider Implications
This development comes after a similar case in Kenya, where a high court halted a similar deal with the US after concerns were raised about the safety of Kenyans' health data.
After returning to office recently, US President Donald Trump has slashed overseas assistance and shut down the key foreign aid agency.
The agency had administered aid for the American government, but Trump argued its expenditure was "inefficient" and his administration was seeking direct bilateral deals to enhance transparency and accountability.
Based on statements, 16 nations in Africa have to date agreed to similar agreements, constituting more than $18.3bn in new funding.
Details of the Declined Agreement
This assistance for Zimbabwe was intended to funded "tackling HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We believe this collaboration might have yielded significant benefits for Zimbabwean communities, particularly the 1.2 million currently on antiretroviral therapy via American-funded initiatives," the Ambassador added.
However, government spokesperson Nick Mangwana argued the arrangement was "unequal".
"The proposal required Zimbabwe to share its genetic material and health information for a long time, without any equivalent assurance of benefiting from any scientific breakthroughs – such as new medicines or tests – that might be developed from that shared data," Mangwana explained.
"In essence, our nation would provide the basic resources for medical research without any certainty that the final treatments would be available to our citizens should a future pandemic emerge."
Sovereignty and Global Health
Mangwana further pointed out that the American exit from the global health body and its push of one-on-one health agreements were undermining structures already established via the international health agency.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing framework created to deal with potential global health emergencies.
"This mechanism is designed to guarantee that when a country provides its information, the resulting advantages – including vaccines and treatments – are shared equitably, not commercialised exclusively by those with the capability to create them."
The government's concerns regarding the US deal "should not be misconstrued as opposition to America," he added.
"We welcome ongoing dialogue with our American counterparts on how future co-operation could be structured in a manner that honours the independence and interests of both nations."
Medical Community Response
The Zimbabwe College of Public Health Physicians (ZCPHP) expressed it recognised the government's concerns, but urged that negotiations need to persist considering much of the nation's HIV programmes relied on external financing.
"In cases where technical issues exist, such as those involving data governance or agreement terms, these can often be resolved via detailed discussion and negotiated safeguards," it said.
The halted deal underscores the ongoing challenges between receiving much-needed foreign assistance and protecting national sovereignty in an ever more data-driven world.